Respiratory syndrome coronavirus‐2 response: Microbiota as lactobacilli could make the difference

Zrelli, Samia; Amairia, Safa; Zrelli, Malek

doi:10.1002/jmv.26746

Cited by 10 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Probiotics are known to secrete beneficial metabolites termed as postbiotics which could promote immunomodulatory effects and antibacterial and antiviral mechanisms; thus, it is unsurprising that probiotics were advocated as potential adjuvant therapy or prevention against SARS-COV-2 infection [28][29][30][31][32][33]. Some postbiotics, including bacteriocins have been proven to migrate across human epithelial cells to exert therapeutic effects [34].…”

Section: Discussionmentioning

confidence: 99%

Potential Adjuvant Therapeutic Effect of Lactobacillus plantarum Probio-88 Postbiotics against SARS-COV-2

et al. 2021

View full text Add to dashboard Cite

In response to the ongoing COVID-19 pandemic, the global effort to develop high efficacy countermeasures to control the infection are being conducted at full swing. While the efficacy of vaccines and coronavirus drugs are being tested, the microbiome approach represents an alternative pathophysiology-based approach to prevent the severity of the infection. In the current study, we evaluated the action of a novel probiotic Lactobacillus plantarum Probio-88 against SARS-COV-2 replication and immune regulation using an in vitro and in silico study. The results showed that extract from this strain (P88-CFS) significantly inhibited the replication of SARS-COV-2 and the production of reactive oxygen species (ROS) levels. Furthermore, compared with infected cells, P88-CFS treated cells showed a significant reduction in inflammatory markers such as IFN-α, IFN-β, and IL-6. Using an in silico molecular docking approach, it was postulated that the antiviral activity of L. plantarum Probio-88 was derived from plantaricin E (PlnE) and F (PlnF). The high binding affinity and formation of hydrogen bonding indicated that the association of PlnE and PlnF on SARS-COV-2 helicase might serve as a blocker by preventing the binding of ss-RNA during the replication of the virus. In conclusion, our study substantiated that P88-CFS could be used as an integrative therapeutic approach along with vaccine to contain the spread of the highly infectious pathogen and possibly its variants.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential Adjuvant Therapeutic Effect of Lactobacillus plantarum Probio-88 Postbiotics against SARS-COV-2

et al. 2021

View full text Add to dashboard Cite

show abstract

“…17 In the context of SARS-CoV-2 infection, lactobacilli may act as a barrier to viral penetration through several mechanisms. 38 Lactobacillus gasseri Kx110A1 was reported to attenuate SARS-CoV-2 infection by inhibiting the expression of a disintegrin and metalloprotease 17 (ADAM 17), 39 an enzyme that participates in ACE2 ectodomain shedding and that has been shown to play a role in the entry of SARS-CoV, since ADAM17 silencing was found to reduce SARS-CoV infection. 40 Moreover, a computational study found that plantaricin, a bacteriocin secreted by Lactiplantibacillus plantarum, may possess SARS-CoV-2 antiviral activity by interacting with the receptor-binding domain (RBD) of the viral spike glycoprotein and thus blocking SARS-CoV-2 cellular entry.…”

Section: Discussionmentioning

confidence: 99%

Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells

Salaris

Scarpa

Elli³

et al. 2021

Gut Microbes

View full text Add to dashboard Cite

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the ongoing global pandemic of coronavirus disease 2019 (COVID-19), which primarily manifests with respiratory distress and may also lead to symptoms associated with the gastrointestinal tract. Probiotics are living microorganisms that have been shown to confer immune benefits. In this study, we investigated the immunomodulatory effects and anti-SARS-CoV-2 activity of three different Lacticaseibacillus probiotic strains, either alone or in combination with lactoferrin, using the intestinal epithelial Caco-2 cell line. Our results revealed that the Lacticaseibacillus paracasei DG strain significantly induced the expression of genes involved in protective antiviral immunity and prevented the expression of proinflammatory genes triggered by SARS-CoV-2 infection. Moreover, L. paracasei DG significantly inhibited SARS-CoV-2 infection in vitro. L. paracasei DG also positively affected the antiviral immune activity of lactoferrin and significantly augmented its anti-SARS-CoV-2 activity in Caco-2 intestinal epithelial cells. Overall, our work shows that the probiotic strain L. paracasei DG is a promising candidate that exhibits prophylactic potential against SARS-CoV-2 infection.

show abstract

“…The authors speculate that increases in gut Lactobacillus numbers may therefore be a host adaptive host response to viral infection. Administration of Lactobacillus strains in mice can decrease asthmatic symptoms (46)(47)(48)(49), decrease airway inflammation and alveolar damage (49,50), and provide protection against respiratory viral infection (23,45,51). Thus, we might expect Lactobacillus numbers to increase in those animals with chronic FURTD signs compared to controls as an adaptive response.…”

Section: Discussionmentioning

confidence: 99%

Chronic clinical signs of upper respiratory tract disease shape gut and respiratory microbiomes in cohabitating domestic felines

Arnold

Hanselmann

Duke

et al. 2022

Preprint

View full text Add to dashboard Cite

Feline upper respiratory tract disease (FURTD), often caused by infections etiologies, is a multifactorial syndrome affecting feline populations worldwide. Because of its highly transmissible nature, infectious FURTD is most prevalent anywhere cats are housed in groups such as animal shelters, and is associated with negative consequences such as decreasing adoption rates, intensifying care costs, and increasing euthanasia rates. Understanding the etiology and pathophysiology of FURTD is thus essential to best mitigate the negative consequences of this disease. Clinical signs of FURTD include acute respiratory disease, with a small fraction of cats developing chronic sequelae. It is thought that nasal mucosal microbiome changes play an active role in the development of acute clinical signs, but it remains unknown if the microbiome may play a role in the development and progression of chronic clinical disease. To address the knowledge gap surrounding how microbiomes link to chronic FURTD, we asked if microbial community structure of upper respiratory and gut microbiomes differed between cats with chronic FURTD signs and clinically normal cats. We selected 8 households with at least one cat exhibiting chronic clinical FURTD, and simultaneously collected samples from cohabitating clinically normal cats. Microbial community structure was assessed via 16S rDNA sequencing of both gut and nasal microbiome communities. Using a previously described ecophylogenetic method, we identified 37 and 27 microbial lineages within gut and nasal microbiomes respectively that significantly associated with presence of active FURTD clinical signs in cats with a history of chronic signs. Overall, we find that nasal and gut microbial communities may contribute to the development of chronic clinical course, but more research is needed to confirm our observations.

show abstract

Respiratory syndrome coronavirus‐2 response: Microbiota as lactobacilli could make the difference

Cited by 10 publications

References 49 publications

Potential Adjuvant Therapeutic Effect of Lactobacillus plantarum Probio-88 Postbiotics against SARS-COV-2

Potential Adjuvant Therapeutic Effect of Lactobacillus plantarum Probio-88 Postbiotics against SARS-COV-2

Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells

Chronic clinical signs of upper respiratory tract disease shape gut and respiratory microbiomes in cohabitating domestic felines

Contact Info

Product

Resources

About